Tabrecta Gains Full FDA Approval for Non-Small Cell Lung Cancer
Drug approved for non-small cell lung cancer with mutation leading to MET exon 14 skipping
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.